WESTERN ONCOLYTICS, LTD
Engineered immunotherapies optimized for cancer treatment
- Sector
- Biotech
- Headquarters
- WESTLAKE, OH
- Founded
- 2013
- Latest Form D
- $2.5M, Jun 2015
- Total capital
- $4.1M
- Federal grants
- $1.3M
- 2 awards · 2019–2020
- Rank in peer group#231 of 326
- Private capital raised
- $2.8M
- 2 Form D · last Jun 2015
- 137 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 3 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · A novel immuno-oncolytic viral therapy for the treatment of non-small cell lung carcinoma$994K
- Federal grantHealth and Human S · Phase II · A novel immuno-oncolytic viral therapy for the treatment of non-small cell lung carcinoma$296K
- Private capital raisedForm D · SEC · 2nd filing$2.5M
- Private capital raisedForm D · SEC · 1st filing$273K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Linked publications#9 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Stephen ThorneResearcherDirectorLinked by $1.3M in grants as PI
- Kurt RoteExecutive Officer, DirectorNamed in SEC Form D filings
- Richard Jones, Sr.DirectorNamed in SEC Form D filings
- Thomas LeonardDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 3- PendingManufacture Of VirusUSPTOApplication PCTUS2019062643
- PendingManufacture Of VirusUSPTOApplication 62770577
- PendingPlatform Oncolytic Vector For Systemic DeliveryUSPTOApplication PCTUS2018058456
Recent research by its founders
- Supplementary Data File 1 from An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T Cells and Promotes Tumor Clearance20260 cites
- Supplementary Data File 2 from An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T Cells and Promotes Tumor Clearance20260 cites
- Supplementary Data File 3 from An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T Cells and Promotes Tumor Clearance20260 cites
Related companies, and why
- TFF PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- ACURASTEM INCSimilar federal contract value in Biotech · null in contracts
- OPHIDION, INC.Similar federal contract value in Biotech · null in contracts
- ELASTRIN THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Paulex Bio Inc.Similar federal contract value in Biotech · null in contracts
- CYTOTERRA INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .